Researchers have compiled a comprehensive genetic architecture atlas for mutant RAS genes in human cancers.
Through extensive single-cell analysis, researchers at MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes.
Lynparza (olaparib) showed clinically meaningful survival benefit as first line therapy in certain patients with ovarian cancer, according to long-term data.
Southwest Oncology Group researchers have found that starting Keytruda (pembrolizumab) before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.
In an international, multicenter phase II clinical trial led by MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma saw their tumors nearly or completely disappear when treated with immunotherapy before surgery.
Newly released results from the phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years.
GRAIL LLC presented final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer.
A new subgroup analysis across the MONALEESA phase III program found that patients with visceral metastases who were treated with Kisqali (ribociclib) plus endocrine therapy in the first-line setting achieved a median OS of 62.7 months compared to 52.1 months for those treated with endocrine therapy alone.
Long-term data from the phase III PRIMA study showing Zejula (niraparib) maintained a sustained and clinically meaningful PFS benefit as a maintenance therapy in patients with first-line ovarian cancer following a response to platinum-based chemotherapy. Importantly, this benefit was sustained across all biomarker subgroups, including BRCAm, HRd and HRp.
Giving standard chemotherapy drugs in a specific sequence for some types of metastatic breast cancer can help reduce overall costs and improve the value of care while preserving quality of life, according to a study led by UNC Lineberger Comprehensive Cancer Center and UNC Gillings School of Global Public Health researchers.
